Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

Completed · Phase 2/Phase 3

Conditions studied: Insulin-Like Growth Factor-1 Deficiency, Growth Disorders

In brief

This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.

Key facts

Study ID

NCT00125190

Run by

Ipsen

People needed

45

Starts

2005-07-01

Expected to finish

2009-01-01

Last updated by the study team

2020-07-27

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronological age ≥ 3
• Chronological age or bone age ≤ 12 for boys and ≤ 11 for girls
• Prepubertal at Visit 1
• Height SD score of < -2
• IGF-1 SD score of < -2

You may not qualify if…

• Prior treatment with GH, IGF-1, or other growth-influencing medications
• Growth failure associated with other identifiable causes (e.g., syndromes, chromosomal abnormality)
• Chronic illness such as diabetes, cystic fibrosis, etc.

Where it is running

• Ipsen — Brisbane, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.